Bindu Nayak is an Endocrinology/Metabolic physician. OpenAlex indexes 5 publications with 645 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
820 N Chelan Ave
Wenatchee, WA 988012028
Telephone
509-663-8711Registry record last updated 12 Aug 2013.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20251 payment
- BETA BIONICS, INC.Program year20251 payment
- Tandem Diabetes Care, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
71.4%Insulin Analog38.1%Lantus Solostar22%Humalog Kwikpen U-10012%Novolog Flexpen11%Basaglar Kwikpen U-1009%Humalog8%Tresiba Flextouch U-2006%Lantus5%Fiasp Flextouch5%Insulin Lispro Kwikpen U-1005%Novolog4%Insulin Lispro3%Tresiba Flextouch U-1002%Toujeo Solostar2%Fiasp2%Humalog Kwikpen U-2002%Toujeo Max Solostar2%Part D<11 patientsGLP-1 receptor agonist17.9%Ozempic74%Trulicity17%Mounjaro9%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
23.1%l-Thyroxine16.7%Levothyroxine Sodium88%Synthroid8%Tirosint4%Part D<11 patientsThyroid Hormone Synthesis Inhibitor3.6%Methimazole100%Part D≥23 patients+ 4 more classes in this area
Sensory organs
2.3%Corticosteroid2.3%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Timing of Levothyroxine Administration Affects Serum Thyrotropin Concentration
The Journal of Clinical Endocrinology & Metabolism
2009 - Concentration Timing of Levothyroxine Administration Affects Serum Thyrotropin2009
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”